UOC
EVFM

UBS O'Connor’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

UBS O'Connor’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-482
Closed -$390K – 817
2015
Q2 		$390K Sell
482
-1,000
-67% -$642K ﹤0.01% 718
2015
Q1 		$1.1M Sell
1,482
-69
-4% -$44.1K 0.01% 499
2014
Q4 		$1.04M Buy
+1,551
New +$1.17M 0.02% 352

Other funds holding EVFM

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

UBS O'Connor's EVFM Position: Q3 2015 in Review

UBS O'Connor sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2015, closing a stake of 482 shares — an estimated $390K sold.

UBS O'Connor first reported a position in EVFM in Q4 2014 and held it in 3 quarters. The position peaked at $1.1M in Q1 2015. 29 funds tracked by Wall St. Rank hold EVFM as of Q3 2015.

  • UBS O'Connor reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • UBS O'Connor sold 482 Evofem Biosciences, Inc. Common Stock shares in Q3 2015, an estimated $390K.
  • UBS O'Connor first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2014 and held it in 3 quarters.
  • UBS O'Connor's Evofem Biosciences, Inc. Common Stock position peaked at $1.1M in Q1 2015.
  • 29 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2015.

Based on UBS O'Connor's 13F filing for Q3 2015, filed 13 Nov 2015.